Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir

• Yoshizaki, Tomokazu

• Wakisaka, Naohiro

• Kondo, Satoru

• Murono, Shigeyuki

• Shimizu, Yoshinori

• Nakashima, Masashi

• Tsuji, Akira

• Furukawa, Mitsuru

Abstract

金沢大学附属病院耳鼻咽喉科

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) associated malignant tumor. Recently, cidofovir, an anti-viral drug which is an acyclic nucleoside analogue, has been reported to have an anti-tumor potential. Two patients with NPC, who had previously received multi-round therapy, were treated with cidofovir. Cidofovir was topically injected in and around the tumor once every 3 weeks (originally 75 mg/ml sulution, diluted to 15 mg/ml just before injection, 37.5 mg of cidofoviratatime).Tumorgrowth was suppressed for several months around the injection site in each patient. EBV-encoded RNAs in situ hybridization revealed the reduction of the tumor cell population; however, the EBER expression was still maintained in the NPC tumor cells. Although the anti-tumor mechanism remains unclear, these results suggest that cidofovir is actually an effective and safe agent for the treatment of NPC. © 2008 Wiley-Liss, Inc.

Journal

• Journal of Medical Virology

  Journal of Medical Virology 80 (5), 879-882, 2008-05-01

  John Wiley & Sons

Keywords

• Chemotherapy
• Cidofovir
• EBERs
• Epstein-Barr virus
• Head and neck cancer
• Nasopharyngeal carcinoma

Details

• CRID: 1050282810960524800
• NII Article ID: 120001135568
• NII Book ID: AA00702400
• ISSN: 01466615
• Web Site: http://hdl.handle.net/2297/9828
• Text Lang: en
• Article Type: journal article
• Data Source:
  • IRDB
  • CiNii Articles